|
Nov 30
|
AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen deal
|
|
Nov 30
|
AbbVie signs $10 billion deal to buy cancer drugmaker ImmunoGen
|
|
Nov 30
|
UPDATE 3-AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen
|
|
Nov 30
|
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
|
|
Nov 30
|
AbbVie joins ADC dealmaking with $10B ImmunoGen buyout
|
|
Nov 8
|
Zacks.com featured highlights include Confluent, Pinterest, ICON and ImmunoGen
|
|
Nov 6
|
Wall Street Analysts See a 40.58% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?
|
|
Nov 4
|
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
|
|
Nov 3
|
ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
|
|
Nov 3
|
When Will ImmunoGen, Inc. (NASDAQ:IMGN) Turn A Profit?
|
|
Nov 2
|
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
|
|
Nov 2
|
Immunogen Inc (IMGN) Reports Q3 2023 Earnings: Net Income of $30.7 Million
|
|
Nov 2
|
ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates
|
|
Nov 2
|
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
|
|
Jul 27
|
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
|
|
Jul 26
|
Institutional investors in ImmunoGen, Inc. (NASDAQ:IMGN) lost 9.0% last week but have reaped the benefits of longer-term growth
|
|
Jul 25
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
|
|
Jul 24
|
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
|
Jul 24
|
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
|